United Kingdom Liquid Biopsy Market By Offering (Testing Service, Kits, Platform, Other consumables), By Technology (Polymerase Chain Reactions (PCR), Next Generation Sequencing (NGS), Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management), By Sample (Blood, Urine, Saliva, Others), By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles, Others), By Application (Oncological and Non-oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Region, Competition Forecast & Opportunities 2018-2028

The United Kingdom Liquid Biopsy Market is anticipated to grow at a significant rate in the projected period of 2024-2028. Liquid biopsy has emerged as a groundbreaking diagnostic tool in the field of oncology, enabling non-invasive detection and monitoring of various types of cancer. The United Kingdom has been at the forefront of embracing this innovative technology, revolutionizing cancer detection and treatment strategies.

Cancer remains a significant healthcare challenge in the United Kingdom, with an increasing incidence and mortality rate. Conventional tissue biopsies, while effective, are invasive, time-consuming, and often provide limited information due to tumor heterogeneity. Liquid biopsy offers a promising alternative, allowing the detection and monitoring of cancer through the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers present in blood or other bodily fluids.

With a few uses already approved by the U.S. Food and Drug Administration (FDA), liquid biopsy is a relatively new test with a number of potentially groundbreaking applications in the treatment of cancer. Its advantages are still being studied. Because of its potential to assist healthcare professionals in diagnosing and monitoring cancer with a straightforward blood test, liquid biopsy tests are an active area of research and development. Liquid biopsy tests are currently being developed to do things that traditional biopsy techniques cannot, such as detecting cancer before a tumor has formed. Even so, more investigation is required to comprehend the potential applications of liquid biopsy. In specific circumstances, they can assist in the diagnosis of certain cancers and guide treatment choices. They might have a lot more applications in the future, leading to the growth of the United Kingdom Liquid Biopsy Market.

Furthermore, liquid biopsy enables real-time monitoring of treatment response, detection of minimal residual disease, and identification of treatment-resistant mutations, facilitating personalized treatment approaches for patients. This is expected to grow the United Kingdom Liquid Biopsy Market in the forecast period. According to Cancer Research UK, lung cancer affects about 46,700 people annually in the United Kingdom alone. Sadly, only 1 in 20 people will live for 10 years or more, and this number has not decreased over the past ten years.

Moreover, collaborations between academic institutions, healthcare providers, and industry players are fostering innovation and driving the adoption of liquid biopsy across the United Kingdom. The National Health Service (NHS) plays a vital role in facilitating the integration of liquid biopsy into routine clinical practice, ensuring equitable access and improved patient outcomes, thus augmenting the growth of the United Kingdom Liquid Biopsy Market.

Download Free Sample Report

High Efficiency of Liquid Biopsy spur its demand in United Kingdom

The field of diagnostics has witnessed significant advancements in recent years, with liquid biopsy emerging as a powerful tool for non-invasive cancer detection and monitoring. In the United Kingdom, liquid biopsy has gained traction due to its high efficiency and potential to revolutionize the landscape of cancer diagnostics, which is expected to propel the growth of United Kingdom Liquid Biopsy Market. Traditional cancer diagnostics often involve invasive procedures such as tissue biopsies, which can be uncomfortable and carry associated risks. Liquid biopsy, on the other hand, offers a minimally invasive alternative by analyzing various biomarkers present in bodily fluids like blood, urine, and cerebrospinal fluid. These biomarkers include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and microRNAs, among others. By monitoring changes in biomarker levels over time, liquid biopsy facilitates real-time assessment of treatment response and disease progression. This dynamic monitoring enables clinicians to make informed decisions regarding treatment adjustments or modifications, leading to the growth of United Kingdom Liquid Biopsy Market. Additionally, liquid biopsy also eliminates the need for invasive surgical procedures, reducing patient discomfort and recovery time. It also allows for repeated testing, enabling longitudinal monitoring of the disease without subjecting patients to multiple invasive procedures. Liquid biopsy provides a comprehensive molecular profile of the tumor, offering insights into its genetic alterations and identifying potential therapeutic targets. This information aids in the selection of appropriate treatment options, improving patient outcomes, which is expected to propel the growth of United Kingdom Liquid Biopsy Market. The of United Kingdom government has recognized the potential of liquid biopsy in advancing cancer diagnostics and has allocated significant funding for research and development in this area. As per the Research Cancer Research Fund, in 2019, 3,87,820 cases of cancer were diagnosed in United Kingdom. Government support and initiatives have created a favorable environment for the growth of the liquid biopsy market.  Collaboration between academic institutions, research organizations, and industry players has facilitated knowledge exchange, development of standardized protocols, and validation of liquid biopsy tests. Such collaborations have accelerated the translation of liquid biopsy from research to clinical applications, hence booming the United Kingdom Liquid Biopsy Market.

Growing Demand for Polymerase Chain Reaction (PCR) Technology drives United Kingdom Liquid Biopsy Market

The United Kingdom's liquid biopsy market is witnessing a significant surge in demand, primarily driven by the growing adoption of polymerase chain reaction (PCR) technology. PCR has emerged as a powerful tool within the liquid biopsy field, enabling highly sensitive and specific detection of genetic alterations in circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs). The technique amplifies specific DNA sequences, allowing for the detection of minute quantities of genetic material associated with tumors. This capability has revolutionized cancer diagnostics and monitoring, offering several advantages over traditional tissue biopsies, leading to the growth of United Kingdom Liquid Biopsy market. One of the main drivers of the growing demand for PCR-based liquid biopsies in the UK is the increasing recognition of their potential for early cancer detection. Traditional tissue biopsies are invasive, require skilled personnel, and often face challenges in obtaining sufficient tissue samples. Liquid biopsies, on the other hand, provide a minimally invasive alternative that can be easily repeated over time to monitor disease progression and treatment response. The advent of targeted therapies and personalized medicine has further propelled the adoption of liquid biopsies in the UK. PCR-based liquid biopsies enable the identification of specific genetic mutations or alterations in tumor DNA, guiding treatment decisions and helping to optimize patient outcomes. By providing real-time information on the genomic landscape of tumors, liquid biopsies contribute to precision medicine approaches, allowing for more effective and tailored therapies. As per Office for National Statistics, in 2021, compared to 10.0% in 2020, the total current healthcare expenditure increased in real terms by 7.1% after accounting for the effects of inflation on the economy as a whole. The United Kingdom has been at the forefront of adopting innovative healthcare technologies, and the growing demand for PCR-based liquid biopsies is a testament to this trend. Leading diagnostic companies and research institutions in the country are actively investing in liquid biopsy research and development, aiming to expand the range of detectable biomarkers and improve the sensitivity and accuracy of the technology, which is expected to grow the United Kingdom Liquid Biopsy Market.

Recent Developments

• In 2020, According to a news release from the NIH National Cancer Institute, the US Food and Drug Administration (FDA) expanded its clearance for two liquid biopsy tests in United Kingdom—Guardant Health's Guardant360 CDx and Foundation Medicine's FoundationOne Liquid CDx—for use as companion diagnostic tests and for general tumor profiling for specific non-small cell lung, prostate, breast, and ovarian cancers.

Mergers and Acquisitions

In March 2023, University of Birmingham collaborated with Nonacus which is a liquid biopsy cancer detection and screening company. The urine-based molecular test, known as GALEAS Bladder, that was launched at the Annual Meeting of the European Association of Urology, can more effectively diagnose bladder cancer and lessen the need for invasive cystoscopies by detecting it rapidly and precisely.

Market Segmentation

United Kingdom Liquid Biopsy Market is segmented into Offering, Technology, Workflow, Sample, Circulating Biomarker, Application, End User, Region and Competitive Landscape. Based on Offering, the United Kingdom Liquid Biopsy Market is divided into Testing Service, Kits, Platform and Other Consumables. Based on Technology, the market is categorized into Polymerase Chain Reactions, Next Generation Sequencing and Others. Based on Workflow, the United Kingdom Liquid Biopsy Market is categorized into Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management. Based on Sample, the market is categorized into Blood, Urine, Saliva and Others. Based on Circulating Biomarker, the market is categorized into Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles and Others. Based on Application, the market is categorized into Oncological and non-Oncological. Based on End User, the market is categorized into Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies. Based on region, the United Kingdom Liquid Biopsy Market is segmented into Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands.

Company Profiles

F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc, PerkinElmer Inc., Illumina, Inc., QIAGEN NV, Dxcover Limited, Abcodia Ltd, Sysmex Corporation, Bio-Rad Laboratories, Inc are some of the key players in the United Kingdom Liquid Biopsy Market.

Report Scope:

In this report, United Kingdom Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

• United Kingdom Liquid Biopsy Market, By Offering:
• Testing Service
• Kits
• Platform
• Other Consumables
• United Kingdom Liquid Biopsy Market, By Technology:
• Polymerase Chain Reactions
• Next Generation Sequencing
• Others
• United Kingdom Liquid Biopsy Market, By Workflow:
• Sample Preparation
• Library Preparation
• Sequencing
• Data Analysis & Management
• United Kingdom Liquid Biopsy Market, By Sample:
• Blood
• Urine
• Saliva
• Others
• United Kingdom Liquid Biopsy Market, By Circulating Biomarker:
• Circulating Tumor Cells (CTCs)
• Cell Free Nucleic Acids
• Exosomes & Extracellular Vesicles
• Others
• United Kingdom Liquid Biopsy Market, By Application:
• Oncological
• non-Oncological
• United Kingdom Liquid Biopsy Market, By End User:
• Clinical Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• United Kingdom Liquid Biopsy Market, By Region:
• Scotland
• South-East
• London
• South-West
• East-Anglia
• Yorkshire & Humberside
• East Midlands

Competitive landscape

Company Profiles: Detailed analysis of the major companies in United Kingdom Liquid Biopsy market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

United Kingdom Liquid Biopsy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]